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What is systems biology?
• The computational and 
mathematical modeling of 
complex biological systems
• A biology-based interdisciplinary 
field that focuses on complex 
interactions within biological 
systems
• Using a holistic approach to 
biological research(1)
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Cancer systems biology:
• Developing an increasingly holistic view of cancer development
and progression
• Understanding how complex cancer-associated deregulations
shape malignant states and phenotypes(2)
• Understanding cancer initiation and progression
• Discovery and implementation of more effective anticancer
therapeutic strategies(3)
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A summary of cancer systems biology approaches to 
guide cancer therapy(2)
8
Cancer
• Caused by corruption of normal biological circuits and
processes to sustain uncontrolled proliferative growth
• Characterized by a complex spectrum of alterations that affect
multiple scales ranging from molecular activity within cells
onto communication between cells and tissues(4)
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Why cancer systems biology?
1. Highly complex patterns of interactions 
leads to great challenges in understanding 
cancer progression and designing effective 
cancer therapy
2. At the genomic level, frequent 
disruption of the DNA   complicating the 
discovery of underlying drivers of tumor 
progression(2)
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3. At the protein level, complex signaling networks makes it
difﬁcult to anticipate the inﬂuences of oncogenic
perturbations and reverse those inﬂuences with
pharmacological agents
4. At the tissue level, interactions between a tumor and its
local environment inﬂuence tumor growth and invasion(2)
11
5. in many cancer types, substantial heterogeneity of molecular
alterations in patient population yields highly variable clinical
responses to the same treatment(2)
 systems biology approaches that can manage and model this
complexity will be needed to identify and validate targets,
biomarkers and discover more effective and less toxic
therapeutic strategies(5)
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PROBING CANCER COMPLEXITY
13
Tissue level
Personalize
d cancer 
medicine
Genomic level
Protein & 
posttransnational
level
PROBING CANCER COMPLEXITY AT THE 
GENOMIC LEVEL
Cancer is a disease driven by the accumulation of genomic and 
epigenomic alterations
• Genomic alterations: 
1.point mutations
2.translocations
3. copy number variations 
• Epigenomic alterations:
1.hyper- or hypomethylation of speciﬁc regions and genes
2. changes in levels of histone modiﬁcations(2)
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genetic and epigenetic alterations:
1) drivers:
confer selective growth advantage and are thus causal for 
malignant transformation and tumor progression.
2) passengers:
accumulate in the course of cell divisions and contribute 
little to malignant phenotypes.
 Systems-level analyses have made creative use of
passenger mutations to uncover potential therapeutic
strategies(2)
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Complexity of the cancer genome:
The rate of genomic alteration occurrence plays a central
role in this evolutionary process(6)
In cancer cells, oncogene-induced DNA replication stress
and/or direct disruptions of DNA repair genes leading to
widespread genomic instability
Cancer cells display extensive intratumoral and intertumoral
heterogeneity(2)
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Intratumor heterogeneity can further seed intertumoral
heterogeneity among different metastases, if :
different metastases arise from distinct founder cells that have
escaped from the primary tumor(3)
 Darwinian point of view:
therapeutic intervention can act as an imposed selective
pressure that potently and rapidly alters subclonal
constitution(2)
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Interrogating the cancer genome using next-generation 
sequencing:
 Next-generation sequencing : ultrafast, high-throughput and
affordable sequencing via massively parallel assessment of
sequence fragments(7)
Whole-genome sequencing of tumor samples with paired
normal tissue is now routinely used(2)
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Whole-exome sequencing :
1) more cost-effective and higher coverage alternative to whole-
genome sequencing
2) detects aberrations that directly alter protein functions with
high sensitivity(6)
RNA sequencing : detect gene expression changes in tumors,
revealed novel expressed variants, gene fusions and splicing
alterations in cancers
single-cell sequencing: valuable information on tumor
heterogeneity and clonal evolution history can be extracted(8)
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Systems approaches for addressing cancer genome 
complexity:
 Even though speciﬁc genomic alterations vary from patient
to patient, they usually result in disruption of a few key
pathways and processes
 Systems-level analysis has provided insights into common
mechanisms underlying cancer pathogenesis(2)
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PROBING CANCER COMPLEXITY AT THE 
PROTEIN AND POSTTRANSLATIONAL LEVELS:
In normal tissues, the homeostasis of signaling networks is
precisely maintained
In cancer cells, genomic and epigenetic alterations leading to
aberrant protein expression or function disrupt this
homeostasis(9)
Loss of negative regulator expression in signaling networks
can remove important brakes on signaling, resulting in
uncontrolled response(6)
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Experimental probing of aberrant function in signaling 
networks:
large-scale protein proﬁling is increasingly used to directly
and systematically monitor signaling pathway activities in
cancer cells
mass spectrometry-based phosphoproteomics: identiﬁes
phosphorylated proteins(2)
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Modeling the dynamics of signaling networks:
Kinetic modeling of protein–protein interactions:
reproduce signaling dynamics in silico and make
quantitative predictions of the effect of various network
alterations
These models demonstrated great potential in identifying
drug response biomarkers, resistance mechanisms, and
synergistic drug combinations(10)
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Data-driven systems biology analysis for dissecting 
aberrant signaling function:
The analysis of proteome-wide proﬁles has provided
important insights into cancer signaling networks and into
how to target their aberrant functions(5)
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PROBING CANCER COMPLEXITY AT THE 
TISSUE LEVEL:
Tumor microenvironment (TME): plays an active role in
tumor progression
Cancer cells beneﬁt from the microenvironment by acquiring
nutrients and various biochemical factors(2)
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targeting the TME may yield efﬁcient and perhaps less toxic
anticancer therapy
The plasticity of tumor microenvironment have led to
emergence of drug resistance in various TME-targeted
therapies(3)
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Experimental approaches for analyzing the tumor 
microenvironment:
mRNA and protein arrays on microdissected tumor biopsy
samples or xenografted tumor lesions:
identiﬁed key factors and pathways, TME-related molecular
signatures predictive of clinical outcome
cross-species hybridization of microarrays:
simultaneous assessment of gene expression in both tumor
and host cells via separate hybridization(2)
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In vivo imaging:
examine tumor–stroma morphology and interactions or assay
speciﬁc molecular markers such as pH, hypoxia or proteases
with ﬂuorescence probes(4)
In vitro culture models of tumor cells with key components of
the microenvironment:
discover important interactions between stroma and tumor
cells
Modeling the TME:
provided important insights into how tumor and the
microenvironment coevolve(2)
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CANCER SYSTEMS BIOLOGY AND 
PERSONALIZED CANCER MEDICINE:
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 computational platform for identifying clinically relevant
alterations based on whole-exome sequencing data from
formalin-ﬁxed, parafﬁn-embedded tumor samples:
Applying this method to patients of various tumor types
successfully identiﬁed potential clinical targets in 15 out of 16
patients(2)
model-based strategy for personalized cancer medicine(2):
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CONCLUSION:
 Cancer is an extremely complex disease featuring systems-
level disruptions(3)
Cancer systems biology operates on large multiscale data set to
develop integrative and predictive models
The integrative and dynamic nature of these models makes
them extremely powerful in addressing some of the major
challenges in cancer biology
As cancer treatment approaches a more personalized era,
cancer systems biology will play a central role in the
development of integrative model-based cancer medicine(2)
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Systems biology databases & tools
Modeling & Simulation                                       Pathway
Network Visualization                                          Protein-pro interaction 
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Modeling & Simulation tools:
CellDesigner (http://www.celldesigner.org/)
Jarnac/JDesigner (http://sbw.kgi.edu/)
COPASI  (http://www.copasi.org/)
E-cell  (http://www.e-cell.org/)
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Network Visualization Tools:
Cytoscape (http://www.cytoscape.org/)
BioTapestry (http://www.biotapestry.org/)
BioUML (http://www.biouml.org/)
CADLIVE  (http://www.cadlive.jp/)
Edinburgh Pathway Editor  
(http://www.bioinformatics.ed.ac.uk/epe/)
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Pathway database:
KEGG(Kyoto Encyclopedia of Genes and Genomes)
(http://www.genome.jp/keg/)
REACTOME  (http://www.reactome.org/)
MetaCyc (http://www.metacyc.org/)
EcoCyc (http://www.ecocyc.org/)
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Protein-protein interaction database:
BINDplus (Biomolecular Object Network Database) 
(http://www.thomsonreuters.com/products_service/scientific/BIN
Dplus)
DIP (The Database of Intracting Proteins)
(http://www.dip.doe-mbi.ucla.edu/dip/Main.cgi)
MINT (The Molecular INTeraction database)
(http://www.mint.bio.uniroma2.it/mint/Welcome.do)
STRING(Search Tool for the Retrieval of Intracting
Genes/Proteins)
(http://www.string.embl.de/)
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